دورية أكاديمية
أعرض في EDS

Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.

التفاصيل البيبلوغرافية
العنوان: Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.
المؤلفون: Schott CR; Department of Pediatrics, University of California San Francisco, San Francisco, California.; Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada., Koehne AL; Department of Pediatrics, University of California San Francisco, San Francisco, California., Sayles LC; Department of Pediatrics, University of California San Francisco, San Francisco, California., Young EP; Department of Pediatrics, University of California San Francisco, San Francisco, California., Luck C; Department of Pediatrics, University of California San Francisco, San Francisco, California.; Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California., Yu K; Department of Pediatrics, University of California San Francisco, San Francisco, California.; Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California., Lee AG; Department of Pediatrics, University of California San Francisco, San Francisco, California., Breese MR; Department of Pediatrics, University of California San Francisco, San Francisco, California., Leung SG; Department of Pediatrics, University of California San Francisco, San Francisco, California., Xu H; Departments of Genetics and Medicine, Stanford University School of Medicine, Stanford University, Stanford, California., Shah AT; Department of Pediatrics, University of California San Francisco, San Francisco, California., Liu HY; Department of Pediatrics, University of California San Francisco, San Francisco, California., Spillinger A; Department of Pediatrics, University of California San Francisco, San Francisco, California., Behroozfard IH; Department of Pediatrics, University of California San Francisco, San Francisco, California., Marini KD; Department of Pediatrics, University of California San Francisco, San Francisco, California., Dinh PT; Department of Pediatrics, University of California San Francisco, San Francisco, California., Pons Ventura MV; Department of Pediatrics, University of California San Francisco, San Francisco, California., Vanderboon EN; Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada., Hazard FK; Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, California., Cho SJ; Department of Pathology, University of California San Francisco, San Francisco, California., Avedian RS; Department of Orthopedic Surgery, Stanford University School of Medicine, Stanford University, Stanford, California., Mohler DG; Department of Orthopedic Surgery, Stanford University School of Medicine, Stanford University, Stanford, California., Zimel M; Department of Orthopedic Surgery, University of California San Francisco, San Francisco, California., Wustrack R; Department of Orthopedic Surgery, University of California San Francisco, San Francisco, California., Curtis C; Departments of Genetics and Medicine, Stanford University School of Medicine, Stanford University, Stanford, California., Sirota M; Department of Pediatrics, University of California San Francisco, San Francisco, California.; Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California., Sweet-Cordero EA; Department of Pediatrics, University of California San Francisco, San Francisco, California.
المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Feb 16; Vol. 30 (4), pp. 849-864.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Denville, NJ : The Association, c1995-
مواضيع طبية MeSH: Osteosarcoma*/drug therapy , Osteosarcoma*/genetics , Osteosarcoma*/metabolism , Bone Neoplasms*/drug therapy , Bone Neoplasms*/genetics , Bone Neoplasms*/metabolism , Cyclic N-Oxides* , Indolizines* , Pyridinium Compounds*, Humans ; Animals ; Mice ; Disease Models, Animal ; Drug Evaluation, Preclinical ; Xenograft Model Antitumor Assays ; Cell Line, Tumor
مستخلص: Purpose: Models to study metastatic disease in rare cancers are needed to advance preclinical therapeutics and to gain insight into disease biology. Osteosarcoma is a rare cancer with a complex genomic landscape in which outcomes for patients with metastatic disease are poor. As osteosarcoma genomes are highly heterogeneous, multiple models are needed to fully elucidate key aspects of disease biology and to recapitulate clinically relevant phenotypes.
Experimental Design: Matched patient samples, patient-derived xenografts (PDX), and PDX-derived cell lines were comprehensively evaluated using whole-genome sequencing and RNA sequencing. The in vivo metastatic phenotype of the PDX-derived cell lines was characterized in both an intravenous and an orthotopic murine model. As a proof-of-concept study, we tested the preclinical effectiveness of a cyclin-dependent kinase inhibitor on the growth of metastatic tumors in an orthotopic amputation model.
Results: PDXs and PDX-derived cell lines largely maintained the expression profiles of the patient from which they were derived despite the emergence of whole-genome duplication in a subset of cell lines. The cell lines were heterogeneous in their metastatic capacity, and heterogeneous tissue tropism was observed in both intravenous and orthotopic models. Single-agent dinaciclib was effective at dramatically reducing the metastatic burden.
Conclusions: The variation in metastasis predilection sites between osteosarcoma PDX-derived cell lines demonstrates their ability to recapitulate the spectrum of the disease observed in patients. We describe here a panel of new osteosarcoma PDX-derived cell lines that we believe will be of wide use to the osteosarcoma research community.
(©2023 The Authors; Published by the American Association for Cancer Research.)
التعليقات: Update of: bioRxiv. 2023 Jan 20:2023.01.19.524562. doi: 10.1101/2023.01.19.524562. (PMID: 36711882)
References: Cells. 2021 Feb 17;10(2):. (PMID: 33671173)
JAMA. 2015 Sep 1;314(9):913-25. (PMID: 26325560)
Ther Adv Med Oncol. 2020 May 10;12:1758835920922055. (PMID: 32426053)
ACS Nano. 2016 Feb 23;10(2):2028-45. (PMID: 26815014)
Vet Pathol. 2022 May;59(3):399-414. (PMID: 35341404)
Clin Cancer Res. 2014 Aug 15;20(16):4200-9. (PMID: 24803583)
Genome Biol. 2014 Feb 03;15(2):R29. (PMID: 24485249)
Clin Exp Metastasis. 2009;26(7):599-610. (PMID: 19363654)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Clin Exp Metastasis. 2004;21(8):747-53. (PMID: 16035619)
Clin Exp Metastasis. 1997 Mar;15(2):164-72. (PMID: 9062393)
Int J Mol Sci. 2020 Sep 19;21(18):. (PMID: 32961800)
Bone. 2000 Mar;26(3):215-20. (PMID: 10709992)
Cancer Invest. 2009 May;27(4):435-42. (PMID: 19212826)
Anticancer Res. 2017 Sep;37(9):4807-4812. (PMID: 28870899)
Nature. 1975 Aug 28;256(5520):751-3. (PMID: 1057046)
Bioinformatics. 2012 Sep 15;28(18):i333-i339. (PMID: 22962449)
Nat Commun. 2019 Aug 8;10(1):3574. (PMID: 31395879)
J Bone Miner Res. 2012 Jan;27(1):58-67. (PMID: 21976359)
Bioinformatics. 2012 Mar 15;28(6):882-3. (PMID: 22257669)
Cancer Lett. 2019 Feb 1;442:262-270. (PMID: 30395907)
Biochim Biophys Acta. 2013 Feb;1832(2):347-54. (PMID: 23195950)
Nat Med. 2018 Feb;24(2):176-185. (PMID: 29334376)
Clin Exp Metastasis. 2003;20(7):665-74. (PMID: 14669798)
Clin Orthop Relat Res. 2018 Jul;476(7):1514-1522. (PMID: 29601385)
Hematol Oncol Clin North Am. 1987 Dec;1(4):655-65. (PMID: 3323177)
Cancer Res. 1993 Oct 15;53(20):4890-5. (PMID: 8402677)
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5. (PMID: 20837533)
Nat Biotechnol. 2013 Mar;31(3):213-9. (PMID: 23396013)
J Pathol. 2019 Nov;249(3):319-331. (PMID: 31236944)
Curr Protoc Bioinformatics. 2016 Dec 8;56:15.9.1-15.9.17. (PMID: 27930809)
Cancer Lett. 2009 Aug 18;281(1):32-41. (PMID: 19342158)
J Clin Oncol. 2002 Feb 1;20(3):776-90. (PMID: 11821461)
Nat Biotechnol. 2017 Apr 11;35(4):314-316. (PMID: 28398314)
Int J Cancer. 1977 Apr 15;19(4):505-10. (PMID: 265298)
Br J Cancer. 2005 Jul 11;93(1):81-8. (PMID: 15942637)
Clin Exp Metastasis. 1999;17(6):501-6. (PMID: 10763916)
Bonekey Rep. 2015 May 06;4:670. (PMID: 25987985)
N Engl J Med. 2021 Nov 25;385(22):2066-2076. (PMID: 34818481)
Cancer. 2019 Oct 15;125(20):3514-3525. (PMID: 31355930)
Nature. 2017 Sep 7;549(7670):96-100. (PMID: 28854174)
Int J Cancer. 1998 May 4;76(3):418-22. (PMID: 9579581)
Bioinformatics. 2016 Apr 15;32(8):1220-2. (PMID: 26647377)
Genome Biol. 2021 Jul 12;22(1):202. (PMID: 34253237)
Cell Rep. 2019 Nov 5;29(6):1675-1689.e9. (PMID: 31693904)
J Clin Invest. 2019 Oct 1;129(10):4377-4392. (PMID: 31498151)
Acta Ortop Bras. 2018 Mar-Apr;26(2):98-102. (PMID: 29983625)
Clin Exp Metastasis. 2015 Oct;32(7):703-15. (PMID: 26278104)
Cancer Res. 2019 Jun 15;79(12):3112-3124. (PMID: 31015228)
J Vis Exp. 2020 Sep 9;(163):. (PMID: 32986024)
Pediatr Blood Cancer. 2019 Apr;66(4):e27579. (PMID: 30548185)
Clin Exp Metastasis. 2005;22(4):319-29. (PMID: 16170668)
Cancer Treat Rev. 2014 May;40(4):523-32. (PMID: 24345772)
Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308)
Br J Cancer. 2011 Nov 8;105(10):1503-11. (PMID: 21979423)
Cell Death Dis. 2016 Oct 13;7(10):e2421. (PMID: 27735939)
Clin Exp Metastasis. 2002;19(6):477-85. (PMID: 12405284)
Oncotarget. 2016 Apr 19;7(16):21114-23. (PMID: 27049730)
Clin Orthop Relat Res. 2018 Jul;476(7):1400-1411. (PMID: 29481344)
Genome Res. 2018 Apr;28(4):581-591. (PMID: 29535149)
J Clin Oncol. 2003 May 15;21(10):2011-8. (PMID: 12743156)
J Natl Cancer Inst. 2019 Nov 1;111(11):1216-1227. (PMID: 30793158)
Cancer Res. 2018 Feb 1;78(3):742-757. (PMID: 29180466)
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. (PMID: 30655315)
Cancer Discov. 2019 Jan;9(1):46-63. (PMID: 30266815)
Sci Rep. 2018 Sep 24;8(1):14294. (PMID: 30250282)
J Am Coll Dent. 2014 Summer;81(3):4-13. (PMID: 25951677)
Lancet Oncol. 2016 Oct;17(10):1396-1408. (PMID: 27569442)
Bioinformatics. 2012 Jul 15;28(14):1811-7. (PMID: 22581179)
Nucleic Acids Res. 2016 Jan 4;44(D1):D1036-44. (PMID: 26531824)
J Mol Diagn. 2015 May;17(3):251-64. (PMID: 25801821)
Oncotarget. 2015 Oct 6;6(30):29469-81. (PMID: 26320182)
معلومات مُعتمدة: S10 OD025022 United States OD NIH HHS; R01 CA243555 United States CA NCI NIH HHS; S10 OD028511 United States OD NIH HHS; P30 CA082103 United States CA NCI NIH HHS; R50 CA274213 United States CA NCI NIH HHS
المشرفين على المادة: 4V8ECV0NBQ (dinaciclib)
0 (Cyclic N-Oxides)
0 (Indolizines)
0 (Pyridinium Compounds)
تواريخ الأحداث: Date Created: 20230913 Date Completed: 20240219 Latest Revision: 20240611
رمز التحديث: 20240611
مُعرف محوري في PubMed: PMC10870121
DOI: 10.1158/1078-0432.CCR-23-0873
PMID: 37703185
قاعدة البيانات: MEDLINE
الوصف
تدمد:1557-3265
DOI:10.1158/1078-0432.CCR-23-0873